Analysts Issue Forecasts for PACB FY2025 Earnings

Pacific Biosciences of California, Inc. (NASDAQ:PACB) – Research analysts at Cantor Fitzgerald lowered their FY2025 earnings estimates for shares of Pacific Biosciences of California in a report released on Tuesday, February 18th. Cantor Fitzgerald analyst R. Osborn now forecasts that the biotechnology company will post earnings per share of ($0.68) for the year, down from their prior estimate of ($0.62). The consensus estimate for Pacific Biosciences of California’s current full-year earnings is ($0.71) per share.

Pacific Biosciences of California (NASDAQ:PACB) last issued its earnings results on Thursday, February 13th. The biotechnology company reported ($0.20) EPS for the quarter, meeting analysts’ consensus estimates of ($0.20). Pacific Biosciences of California had a negative net margin of 200.40% and a negative return on equity of 42.89%. The business had revenue of $39.22 million for the quarter, compared to the consensus estimate of $39.20 million. During the same quarter last year, the firm posted ($0.27) EPS.

PACB has been the topic of several other research reports. Stephens reaffirmed an “overweight” rating and set a $2.50 price target on shares of Pacific Biosciences of California in a research note on Friday, February 14th. Piper Sandler lifted their price target on shares of Pacific Biosciences of California from $2.00 to $2.50 and gave the stock a “neutral” rating in a research note on Monday, November 11th. UBS Group downgraded shares of Pacific Biosciences of California from a “buy” rating to a “neutral” rating and set a $2.00 price target on the stock. in a research note on Monday, November 11th. StockNews.com raised shares of Pacific Biosciences of California to a “sell” rating in a research note on Friday, February 14th. Finally, The Goldman Sachs Group dropped their price target on shares of Pacific Biosciences of California from $1.75 to $1.50 and set a “neutral” rating on the stock in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $2.83.

Pacific Biosciences of California Stock Performance

Shares of PACB stock opened at $1.77 on Thursday. The company’s fifty day simple moving average is $1.78 and its 200-day simple moving average is $1.79. Pacific Biosciences of California has a 52 week low of $1.16 and a 52 week high of $6.09. The company has a debt-to-equity ratio of 1.97, a current ratio of 9.74 and a quick ratio of 8.64.

Insider Activity

In other news, insider Oene Mark Van sold 34,405 shares of Pacific Biosciences of California stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $2.03, for a total value of $69,842.15. Following the completion of the transaction, the insider now directly owns 1,597,454 shares of the company’s stock, valued at approximately $3,242,831.62. The trade was a 2.11 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Michele Farmer sold 24,349 shares of Pacific Biosciences of California stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $1.88, for a total transaction of $45,776.12. Following the completion of the transaction, the insider now directly owns 187,592 shares of the company’s stock, valued at $352,672.96. This trade represents a 11.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. PCA Investment Advisory Services Inc. boosted its stake in Pacific Biosciences of California by 50.0% during the 4th quarter. PCA Investment Advisory Services Inc. now owns 15,000 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 5,000 shares during the period. Creative Planning boosted its stake in Pacific Biosciences of California by 30.8% during the 3rd quarter. Creative Planning now owns 32,409 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 7,629 shares during the period. Hsbc Holdings PLC boosted its stake in Pacific Biosciences of California by 10.3% during the 4th quarter. Hsbc Holdings PLC now owns 86,809 shares of the biotechnology company’s stock valued at $154,000 after purchasing an additional 8,106 shares during the period. Atria Investments Inc boosted its stake in Pacific Biosciences of California by 85.7% during the 3rd quarter. Atria Investments Inc now owns 21,968 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 10,138 shares during the period. Finally, Impact Partnership Wealth LLC boosted its stake in Pacific Biosciences of California by 29.5% during the 4th quarter. Impact Partnership Wealth LLC now owns 50,735 shares of the biotechnology company’s stock valued at $93,000 after purchasing an additional 11,566 shares during the period.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.